Veprena - Instructions For Use, Indications, Doses, Analogues

2024 Author: Rachel Wainwright | [email protected]. Last modified: 2023-12-15 07:39

Veprene

Instructions for use:

1. Release form and composition
2. Indications for use
3. Contraindications
4. Method of application and dosage
5. Side effects
6. Special instructions
7. Drug interactions
8. Analogs
9. Terms and conditions of storage
10. Terms of dispensing from pharmacies

Veprena is a drug that affects calcium-phosphorus metabolism.

Release form and composition

Dosage form - dosed nasal spray: colorless transparent liquid without impurities [14 doses (2 ml) in colorless glass vials with a dosing device, in a cardboard box 1 or 2 vials].

Active substance: calcitonin, in 1 dose - 200 IU (international units).

Excipients: water for injection, sodium chloride, benzalkonium chloride, concentrated hydrochloric acid (up to pH 3.7).

Indications for use

postmenopausal osteoporosis;
deformans osteitis (Paget's disease);
bone pain due to osteolysis and / or osteopenia;
neurodystrophic diseases of various etiologies, including those due to shoulder-scapular syndrome, reflex dystrophy, causalgia, post-traumatic osteoporosis, medicinal neurotrophic disorders.

Contraindications

Veprene is contraindicated in case of hypersensitivity to any of its components.

It is not recommended to prescribe the drug to patients under the age of 18, since there are no data on the efficacy and safety of its use in this age group.

According to research data, calcitonin has neither teratogenic nor embryotoxic effect, however, there is no clinical data on the safety of its use during pregnancy, therefore, the drug is not indicated for pregnant women.

Whether calcitonin penetrates into breast milk has not been reliably established, and therefore it is not prescribed for women who are breastfeeding.

Method of administration and dosage

Veprene is used intranasally. The introduction of the nasal spray is recommended to be carried out alternately: in one or the other nasal passage.

Recommended dosage regimens:

osteoporosis: 200 IU per day, long-term treatment;
bone pain associated with osteopenia and / or osteolysis: 200 IU 1-2 times a day, the course of treatment is at least 3 months. When carrying out long-term therapy, the initial daily dose should be reduced and / or the interval between injections should be increased;
Paget's disease: 200 IU per day, in some cases at the beginning of treatment, the daily dose is increased to 400 IU in several doses. The duration of treatment is from several months to several years;
neurodystrophic diseases: 200 IU per day for 2-4 weeks. If necessary, in addition, for another 6 weeks, appoint 200 IU every other day.

Application rules

You should never shake the bottle, otherwise bubbles will form inside, which may lead to incorrect dosing of the drug.

Before the first use, remove the protective cap and test sprays to allow air to escape from the tube. To do this, holding the bottle strictly vertically, you need to press the plunger 3 times. Possible splashing of the solution is provided, therefore it does not affect the subsequent number of doses.

Rules for subsequent use:

remove the protective cap;
tilt your head slightly forward and insert the tip into the nasal passage so that it is in line with the nasal passage;
press the piston once;
remove the tip from the nose;
take a few vigorous nasal breaths to prevent the drug from flowing out;
repeat the procedure from the second nostril, if 2 injections are prescribed at one time;
wipe the handpiece with a dry, clean cloth and put on the protective cap.

Immediately after the introduction of Veprena, you should not clear the nose.

Side effects

on the part of the respiratory system: very often (≥ 1/10) - soreness in the nasal cavity, sneezing, dryness in the nasal cavity, swelling of the nasal mucosa, irritation, congestion, erythema of the nasal mucosa, rhinitis, excoriation in the nasal cavity, unpleasant odor, allergic rhinitis; often (≥ 1/100, <1/10) - sinusitis, nosebleeds, pharyngitis, ulcerative rhinitis; sometimes (≥ 1/1000, <1/100) - cough;
from the immune system: rarely (≥ 1/10 000, <1/1000) - hypersensitivity reactions, anaphylactoid or anaphylactic reactions, anaphylactic shock;
on the part of the cardiovascular system: often - hot flashes; sometimes - arterial hypertension;
from the nervous system: often - taste disturbances, headache, dizziness;
on the part of the musculoskeletal system: often - arthralgia; sometimes - pain in muscles and bones;
from the digestive system: often - diarrhea, nausea, abdominal pain; sometimes vomiting;
from the urinary system: rarely - polyuria;
from the senses: sometimes - visual disturbances;
on the part of the skin: rarely - generalized rash;
general disorders: often - increased fatigue; sometimes - facial edema, flu-like syndrome, generalized and peripheral edema; rarely - chills;
local reactions: rarely - itching.

In case of an overdose, the following are possible: dizziness, hot flashes, nausea, vomiting (symptomatic treatment), hypokalemia, manifested by muscle twitching and paresthesias (administration of calcium gluconate is shown).

special instructions

In the treatment of osteoporosis, the simultaneous use of adequate doses of calcium and vitamin D is recommended to prevent progressive bone loss.

As a peptide, salmon calcitonin can cause systemic allergic reactions, including anaphylactic shock. Patients who suspect an increased sensitivity to calcitonin should consult a doctor before using Veprene.

With long-term treatment, antibodies to calcitonin may form, but this usually does not affect the clinical efficacy of the drug.

In patients with Paget's disease who have been receiving Veprene for a long time, an addictive phenomenon is possible, which, presumably, has nothing to do with the formation of antibodies, but is a consequence of saturation of the binding sites. In this case, it is recommended to take a break from treatment.

In connection with the possible development of such side effects as visual impairment, increased fatigue and dizziness, during treatment, it is recommended to be careful when working with complex mechanisms and driving vehicles.

Drug interactions

Calcitonin can reduce plasma concentrations of lithium, and therefore may require dose adjustment.

Analogs

Veprene's analogs are: Alostin, Miacaltsik.

Terms and conditions of storage

Store in a dark place at a temperature of 2-8 ° C. Keep out of the reach of children.

Shelf life is 2 years.

Terms of dispensing from pharmacies

Dispensed by prescription.

Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!